Orion Selected to Present at OBIO Investment Submit in February
We’ve been selected to present at the 2021 OBIO Investment Summit, online Feb 9-10, 2021 – Canada’s Premier Health Science Investment Event. Join us in February to find out more
Chemokine Analogs: Unlocking the Power of the Immune System
We are engineering novel chemokine analogs which have the potential to offer superior potency and safety profiles versus traditional drug classes of small molecules and antibodies
Leading to the development of promising new therapies for Cancer and other serious diseases
Our lead drug candidate – OB-002 – has demonstrated
best-in-class potency as well as an excellent safety profile in pre-clinical testing and is now in a phase 1 clinical trial
A Growing Pipeline
We are accelerating the identification and lead optimization of chemokine analogs and other small proteins, using our proprietary Drug Discovery Platform. Current efforts are focused on the identification of novel chemokine analogs for the treatment of other serious diseases.
Recognized
Leadership
Previous
Next
Orion Biotechnology Project Awarded Grant to Advance Drug Discovery
January 14, 2021
Genève SWITZERLAND, Jan 14, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that its drug discovery project was
Therapeutic Developed using Novel Approach to Drug Discovery has Successfully Completed Phase 1 Clinical Trial
October 16, 2020
OTTAWA, Canada, Oct. 15, 2020 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
July 31, 2020
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
